News Summary

OpenAI, renowned for its advancements in artificial intelligence, has partnered with Retro Biosciences, a startup focused on longevity research, to develop an AI model aimed at extending human life by a decade. The collaboration has led to the creation of GPT-4b micro, a specialized AI model designed to re-engineer proteins, particularly the Yamanaka factors, which are instrumental in transforming human skin cells into stem cells resembling those of younger individuals. This research marks OpenAI’s inaugural venture into biological data, with the potential to revolutionize longevity science and contribute significantly to the development of human organs and cell replacement therapies. The initiative is backed by Sam Altman, CEO of OpenAI, emphasizing the growing intersection of AI and biotechnology.